For ophthalmic use only. Shake the bottle well before each use. Instill one drop into the conjunctival sac of the affected eye(s). Avoid touching the dropper tip to the eye or any other surface to prevent contamination. If more than one topical ophthalmic drug is being used, they should be administered at least 5 minutes apart.

Brinzolamide inhibits carbonic anhydrase in the ciliary body of the eye. This inhibition reduces the formation of bicarbonate ions, which in turn reduces the secretion of aqueous humor, leading to a decrease in intraocular pressure.

• •Hypersensitivity to the active substance, other sulfonamides, or to any of the excipients.
• •Patients with severe renal impairment (creatinine clearance < 30 mL/min).
• •Patients with hyperchloraemic acidosis.

Store at 2°C to 25°C (36°F to 77°F). Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Keep out of reach of children.

Ocular overdose is unlikely to cause systemic toxicity due to low systemic absorption. If accidentally ingested, symptoms may include electrolyte imbalance, acidosis, and central nervous system effects. Treatment should be symptomatic and supportive.

Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. Lactation: It is not known whether brinzolamide is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.